Bioness Company Information

About Bioness

Bioness is the leading provider of implantable and external neuromodulation systems, robotic systems and software therapy programs that provide functional and therapeutic benefits for individuals affected by pain, orthopedic injuries, and other disorders of the central nervous system.

With the support of entrepreneur and philanthropist Alfred E. Mann, Bioness was formed in 2004 to help patients with neurological impairments regain their independence. Since then the company has launched many products to worldwide markets.

Bioness remains part of the Alfred Mann Foundation company portfolio.

Alfred Mann

Bioness was founded by Alfred E. Mann, a physicist, investor, entrepreneur, and philanthropist. During his career, Mr. Mann founded and largely funded 17 companies, bringing many scientific breakthroughs to the medical community, including:

Cochlear implants from Advanced Bionics
Retinal implants from Second Sight
Insulin delivery from Medtronic
Cardiac rhythm management from St. Jude
Spinal cord stimulation from Boston Scientific
Functional rehabilitation from Bioness
Peripheral nerve stimulation (PNS) from Bioness

StimRouter Milestones

The StimRouter Neuromodulation System is an innovative technology that provides permanent relief for chronic pain. StimRouter therapy fills an important gap in the treatment algorithm between medications and more invasive procedures.

2004

Bioness develops technology that lays the foundation for the StimRouter PNS neuromodulation system.
2014

StimRouter received CE Mark approval to treat chronic pain of peripheral nerve origin
2015

StimRouter received FDA 510(k) approval to treat chronic pain of peripheral nerve origin
2016

Results from the Chronic Pain Randomized Control Trial published in
2016

StimRouter launched in the US and European markets as the only PNS device specifically designed to treat chronic peripheral nerve pain. Initiated an IDE clinical study for the use of StimRouter PNS as a treatment for overactive bladder and fecal incontinence.
2018

StimRouter receive Health Canada Approval for the treatment of chronic peripheral nerve pain
2019

Received CE Mark for the treatment of overactive bladder. StimRouter received additional FDA 510(k) approval for product innovations. StimRouter data highlighted in five clinical publications including a prospective case series in Pain Management.
2020

StimRouter receives CE Mark for faecal incontinence.